Single Follicular Dexarelix for LH Suppression During Ovarian Stimulation in Oocyte Donors.

Single Follicular Dexarelix, a New Long Acting GnRH- Antagonist for LH Suppression During Ovarian Stimulation in Oocyte Donors. A Randomised Control Trial.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03861715

Enrollment

180

Registered

2019-03-04

Start date

2017-01-31

Completion date

2021-12-31

Last updated

2020-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Premature Ovarian Failure

Keywords

antagonist protocol, degarelix antagonist protocol, degarelix, IVF

Brief summary

A randomized prospective study in the evaluation of the long acting GnRH antagonist Degarelix against the classical multidose regime with Ganirelix for LH suppression during the follicular phase of an ovarian stimulation cycle in oocyte donors.

Detailed description

A randomized prospective study of the use of single dose of the long acting GnRH antagonist Degarelix for ovarian stimulation cycle in oocyte donors: Ovarian stimulation started on cycle Day2 with gonadotropins 175-300 IU and either GnRH antagonist single dose Degarelix or multidose GnRH antagonist Ganirelix initiated on Day6 of the stimulation cycle. Agonist triggering was used in both groups for oocyte maturation. Blastocyst formation rate and Live Birth Rates were estimated for both groups.

Interventions

DIAGNOSTIC_TESTlive birth rate

The blastulation rate and live birth rate according to the protocol of COS

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 34 Years

Healthy volunteers

Yes

Inclusion criteria

* age 20-34 years; * body mass index (BMI) 18-29kg/m2; * regular menstrual cycle of 26-35 days, * AMH levels age appropriate (≥2.3 ng/ml) * early follicular- phase serum concentration of FSH within normal limits (1-12 IU/l).

Exclusion criteria

* women with diabetes and other metabolic disease * women with hereditary genetic diseases; * women with heart disease, QT prolongation,heart failure * elevated liver enzymes, liver failure, hepatitis * women with inflammatory or autoimmune disease * abnormal karyotype; * endometriosis stage III/IV; * history of recurrent miscarriage; * severe OHSS in a previous stimulation cycle or any contraindication for the use of gonadotrophins.

Design outcomes

Primary

Measure	Time frame	Description
Live birth rate according to stimulation protocol	Up to 38 weeks after embryo transfer	Live birth rate according to stimulation protocol

Secondary

Measure	Time frame	Description
Blastulation rate according to stimulation protocol	Up to 6 days post oocyte retrieval	Blastulation rate according to stimulation protocol

Countries

Greece

Contacts

Primary ContactEvaggelos Papanikolaou, MD,PhD

drvagpapanikolaou@yahoo.gr00302310424294

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026